Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.
Lab-grown immune cells from umbilical cord blood, combined with existing antibody therapy, show early promise against a deadly childhood cancer in the first treated patients.
This first translational study demonstrates that umbilical cord blood NK cells, expanded ex vivo, overcome dose-intensive chemotherapy-induced NK cell depletion and synergize with anti-GD2 antibody therapy in high-risk neuroblastoma, achieving tumor responses in the first two clinical cases with a favorable safety profile. A phase I trial (NCT06631391) is now ongoing, bridging strong mechanistic and preclinical evidence into formal clinical evaluation for this lethal pediatric cancer.
What the study was
- Study design
- Translational study (preclinical + clinical proof-of-concept, phase I trial ongoing)
- Population
- Children with high-risk, relapsed/refractory neuroblastoma; clinical proof-of-concept in 2 patients; phase I trial ongoing (NCT06631391)
- Sample size
- 2
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oncoimmunology
Why it surfaced
First translational study of UCB-NK + anti-GD2 combination in neuroblastoma, with compelling preclinical mechanistic data and clinical proof-of-concept in 2 patients; active phase I trial demonstrates this has moved beyond hypothesis into clinical investigation for a high-unmet-need pediatric cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.